What is Cogent Biosciences Price-to-Free-Cash-Flow?
As of today (2025-05-14), Cogent Biosciences's share price is $4.99.
Cogent Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.04. Hence, Cogent Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Cogent Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:
COGT's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 29.92 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -8.70% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 16.20% per year.
During the past 10 years, Cogent Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 33.50% per year. The lowest was -22.50% per year. And the median was 9.45% per year.
Cogent Biosciences Price-to-Free-Cash-Flow Historical Data
The historical data trend for Cogent Biosciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cogent Biosciences's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Cogent Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Price-to-Free-Cash-Flow falls into.
Cogent Biosciences's Share Price of today is $4.99. Cogent Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Cogent Biosciences Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Cogent Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COGT has been successfully added to your 